FDA-approved drug shows promise against ALS in mice

[Joachim]

The cause of amyotrophic lateral sclerosis (ALS)—a disabling neurodegenerative disease that affects nerve cells in the brain and spinal cord and leads to weakened muscles and early death—is not fully understood, but accumulating evidence suggests that inflammatory processes may play a role in the initiation and progression of the condition. In research led by investigators at Massachusetts General Hospital (MGH) and published in Scientific Reports, treatment with an anti-inflammatory drug delayed the onset of disease in a mouse model of ALS.

Link naar het originele artikel